Pfizer Inc.
CBOE CATotal Valuation
Pfizer Inc. carries a market capitalization of 177.98B, placing it among publicly traded companies globally. Its enterprise value stands at 202.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 177.98B |
| Enterprise Value | 202.79B |
Share Statistics
Pfizer Inc. currently has 5.70B shares outstanding.
| Shares Outstanding | 5.70B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Pfizer Inc. trades at a trailing price-to-earnings ratio of 20.27. The price-to-sales ratio is 2.40, and the price-to-book ratio stands at 1.29.
| PE Ratio | 20.27 |
| PS Ratio | 2.40 |
| PB Ratio | 1.29 |
| P/TBV Ratio | -4.52 |
| P/FCF Ratio | 10.52 |
| P/OCF Ratio | 12.67 |
Enterprise Valuation
On an enterprise value basis, Pfizer Inc. trades at an EV/EBITDA multiple of 8.51 and an EV/FCF ratio of 11.90. The EV/Sales ratio of 3.20 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.76 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.20 |
| EV / EBITDA | 8.51 |
| EV / EBIT | 11.76 |
| EV / FCF | 11.90 |
Financial Position
Pfizer Inc. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 70.49, indicating elevated leverage, while an interest coverage ratio of 8.88 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.25 |
| Quick Ratio | 0.85 |
| Debt / Equity | 70.49 |
| Debt / EBITDA | 2.67 |
| Interest Coverage | 8.88 |
Financial Efficiency
Pfizer Inc. posts a return on equity of 6.30 and a return on invested capital of 10.54.
| Return on Equity (ROE) | 6.30 |
| Return on Assets (ROA) | 3.60 |
| Return on Invested Capital (ROIC) | 10.54 |
| Return on Capital Employed (ROCE) | 5.50 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.56 |
Taxes
Over the trailing twelve months, Pfizer Inc. has paid 384.00M in income taxes, reflecting an effective tax rate of 4.86.
| Income Tax | 384.00M |
| Effective Tax Rate | 4.86 |
Stock Price Statistics
Pfizer Inc.'s stock has declined approximately -8.04498% over the past 52 weeks. The 50-day moving average sits at 11.42, while the 200-day moving average is 11.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -8.04498% |
| 50-Day Moving Average | 11.42 |
| 200-Day Moving Average | 11.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Pfizer Inc. generated 63.31B in revenue and converted that into 7.49B in net income, yielding earnings per share of 0.45. EBITDA reached 23.84B, while operating income came in at 17.25B.
| Revenue | 63.31B |
| Gross Profit | 46.54B |
| Operating Income | 17.25B |
| Pretax Income | 7.91B |
| Net Income | 7.49B |
| EBITDA | 23.84B |
| EBIT | 17.25B |
| Earnings Per Share (EPS) | 0.45 |
Balance Sheet
Pfizer Inc. holds 13.08B in cash and equivalents against 63.73B in total debt, resulting in a net debt position of 62.03B. Total book value stands at 117.72B, with working capital of 8.47B providing operational flexibility.
| Cash & Cash Equivalents | 13.08B |
| Total Debt | 63.73B |
| Net Debt | 62.03B |
| Equity (Book Value) | 117.72B |
| Book Value Per Share | 7.03 |
| Working Capital | 8.47B |
Cash Flow
Pfizer Inc. produced 11.98B in operating cash flow over the past twelve months. After subtracting -2.50B in capital expenditures, free cash flow totaled 9.48B - equivalent to 0.57 per share.
| Operating Cash Flow | 11.98B |
| Capital Expenditures | -2.50B |
| Free Cash Flow | 9.48B |
| FCF Per Share | 0.57 |
Margins
Pfizer Inc. operates with a gross margin of 73.51, reflecting its pricing power and cost economics. The operating margin of 27.24 and net profit margin of 11.83 provide insight into operational efficiency.
| Gross Margin | 73.51 |
| Operating Margin | 27.24 |
| Pretax Margin | 12.49 |
| Profit Margin | 11.83 |
| EBITDA Margin | 37.65 |
Dividends & Yields
The company's payout ratio of 129.27 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.58 |
| Dividend Yield | N/A |
| Payout Ratio | 129.27 |
| Shareholder Yield | 5.22 |
| FCF Yield | 9.51 |
Scores
Pfizer Inc. posts an Altman Z-Score of 4.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.30 |